Breast Cancer Research and Treatment

Papers
(The H4-Index of Breast Cancer Research and Treatment is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review117
Letter to the BRCT editor86
Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation62
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience62
Management and outcomes of men diagnosed with primary breast cancer57
Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers55
Women with metastatic breast cancer don't just follow step-count trends, they exceed them: an exploratory study54
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer51
Racial/ethnic and socioeconomic differences in breast cancer surgery performed and delayed treatment: mediating impact on mortality50
Trends in surgery and adjuvant treatment for early-stage breast cancer: a population-based study in Queensland, Australia49
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer47
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients43
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe42
Retraction Note to: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression42
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy37
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival36
Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS36
Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors34
Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis33
Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial33
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?31
Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer31
Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews31
Radiotherapy, chemotherapy, and heart disease31
Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis30
Early experience of robotic axillary lymph node dissection in patients with node-positive breast cancer30
Effect of neighborhood deprivation index on breast cancer survival in the United States29
Mitochondrial tRNA fragment, mt-tRF-Tyr-GTA-001 (tRF-21-X3OJI8EWB), in breast cancer and its potential clinical implications29
Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer28
Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy28
0.030248165130615